This announcement is a separate document:
亚虹医药：江苏亚虹医药科技股份有限公司自愿披露关于APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌试验Ⅱ期临床试验结果的公告
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the results of the Phase II clinical trial of APL-1202 oral combined with tirelizumab as a new adjuvant treatment for muscle-invasive bladder cancer
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated